Tumor-associated Proteolysis

Prof. Dr. Viktor Magdolen

Extracellular proteolytic processes play an important role for the regulation of cell-cell and cell-matrix contacts. Under physiological conditions, many different proteases (mostly serine, cysteine and matrix metallo proteases) form a complex extracellular network, which is counter-balanced by a series of natural inhibitors. Under pathophysiological conditions, e.g. in solid tumors, often a dysregulation of certain proteases or inhibitors is observed resulting in an increased tumor growth, invasion and metastasis. In our group, we mainly focus on the analysis of the tumor biological role of extracellular serine proteases and their associated proteins as well the clinical relevance of these factors concerning prognosis and response to treatment.

Seitz S, Dreyer T, Stange C, Steiger K, Bräuer R, Scheutz L, Multhoff G, Weichert W, Kiechle M, Magdolen V, Bronger H (2022) CXCL9 inhibits tumor growth and drives anti-PD-L1 therapy in ovarian cancer. Br J Cancer, in press.

Panoutsopoulou K, Dreyer T, Dorn J, Obermayr E, Mahner S, van Gorp T, Braicu I, Zeillinger R, Magdolen V, Avgeris M, Scorilas A (2021) tRNAGlyGCC-derived internal fragment (i-tRF-GlyGCC) in ovarian cancer treatment outcome and progression. Cancers (Basel) 14:24

Soelch S, Beaufort N, Loessner D, Kotzsch M, Reuning U, Luther T, Kirchner T, Magdolen V (2021) Rab31-dependent regulation of transforming growth factor ß expression in breast cancer cells. Mol Med 27:158

Candido JB, Maiques O, Boxberg M, Kast V, Peerani E, Tomás-Bort E, Weichert W, Sananes A, Papo N, Magdolen V, Sanz-Moreno V, Loessner D (2021) Kallikrein‐related peptidase 6 is associated with the tumour microenvironment of pancreatic ductal adenocarcinoma. Cancers (Basel) 13:3969

Dreyer TF, Kuhn S, StangeC, Heithorst N, Schilling D, Jelsmaa J, Sievert W, Seitz S, Stangl S, Hapfelmeier A, Noske A, Wege AK, Weichert W, Ruland J, Schmitt M, Dorn J, Kiechle M, Reuning U, Magdolen V, Multhoff G, Bronger H (2021) The chemokine CX3CL1 improves trastuzumab efficacy in HER2 low expressing cancer in vitro and in vivo. Cancer Immunol Res 9:779-89

Riedel M, Bronger H, Magdolen V, Dreyer T (2021) The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer. Exp Rev Mol Diag 21:535-45

Kryza T, Khan T, Lovell S, Harrington BS, Yin J, Porazinski S, Pajic M, Koistinen H, Rantala J, Dreyer T, Magdolen V, Reuning U, He Y, Tate E, Hooper JD (2021) Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1. Nature Chem Biol 17:776-83

Ari F, Napieralski R, Akgun O, Magdolen V, Ulukaya E (2021) Epigenetic modulators combination with chemotherapy in breast cancer cells. Cell Biochem Funct 39:571-83

Gong W, Zhu C, Liu Y, Muckenhuber A, Bronger H, Scorilas A, Kiechle M, Dorn J, Magdolen V, Dreyer T (2021) Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer. Am J Trans Res 13:1594-1606

Napieralski R, Schricker G, Auer G, Aubele M, Perkins J, Magdolen V, Ulm K, Hamann M, Walch A, Weichert W, Kiechle M, Wilhelm OG (2021) PITX2 DNA-methylation: predictive versus prognostic value for anthracycline-based chemotherapy in triple-negative breast cancer patients. Breast Care 16:523-531